Update on Myasterix study: Safety report summary
The Myasterix Phase 1b study (EudraCT 2015-002880-41) is followed by a Data Review Committee which conducted a formal safety data review in August and then in December 2016.
Belgian investment & collaboration forum 22 November 2016
Nicolas Havelange and Stéphane Huberty, participated in the Belgian investment and collaboration forum on the 22nd of November 2016
The 3rd MYASTERIX general meeting took place in Paris on 22-23 September 2016. It was the opportunity for the partners to present and discuss the progress made so far, at over halfway through the project, since the start of the project in 2013.
2016 BIO International Convention
June 6-9th, 2016
CURAVAC participated in BIO2016 on 6-9 June 2016
June 1st, 2016
The Belgian and Dutch patients associations on Myasthenia Gravis organised a webinar (in Dutch) on the clinical trial of the therapeutic vaccine developed in MYASTERIX project. The webinar took place the 1st June 2016 from 18.00 to 19.00 CET.
To view the webinar:
Start of the clinical study
The phase 1b study has started at the Antwerp University Hospital (Belgium) and is currently recruiting participants.
MYASTERIX is a 5-year European Collaborative Project supported by the European Commission under the Health Cooperation Work Programme of the 7th Framework Programme under the Grant Agreement nº 602420.